The DEA’s Fentanyl Profiling Program (FPP) performs in-depth chemical analyses on fentanyl and fentanyl-related samples obtained from seizures throughout the United States. This report summarizes the findings for these analyses for Calendar Year 2021. FPP data is not intended to reflect U.S. market share, but is rather a snapshot of...

DEA Administrator Anne Milgram's statement on a potential mass fentanyl poisoning event in Gadsden County, Florida on July 2, 2022.

The DEA is seeing a nationwide spike in fentanyl-related mass-overdose events involving three or more overdoses occurring close in time at the same location. In just the past two months, there have been at least 7 confirmed mass overdose events across the United States resulting in 58 overdoses and 29...

DEA’s mission is to keep American communities safe and healthy and we are in the midst of an overdose crisis that has reached a devastating new height. 265 people die every day from drug overdoses. Countless more [people] overdose and are fortunate to survive. This is a national crisis. It...

Counterfeit pills are fake medications that have different ingredients than the actual medication. They may contain no active ingredient, the wrong active ingredient, or have the right ingredient but in an incorrect quantity. Counterfeit pills may contain lethal amounts of fentanyl or methamphetamine and are extremely dangerous because they often...

The increasing availability of illicit opioids is the most significant drug threat in Pennsylvania. The Philadelphia Field Division (PFD) monitors this threat closely, periodically reviewing multiple data indicators, in conjunction with investigative information, to continually assess the threat, then share analytical findings with stakeholders in federal, state, and municipal governments.

Due to the efforts of DEA and our partners, from January 2017 through August 2020, we have seen the number of opioid prescriptions drop nearly 37 percent, a reduction in over 47 percent of opioids dispensed, and most importantly -- an 18 percent drop in prescription overdose deaths over the...

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) is advising law enforcement and public health counterparts of the increased availability of counterfeit controlled prescription drugs (CPDs) – commonly sold as legitimate CPDs with most containing fentanyl/ fentanyl-related compounds (FRC) – in Pennsylvania and Delaware.

The PDIP strives to maintain situational awareness of the threat posed by prescription opioids in Pennsylvania, and to share these analyses with stakeholders in federal, state, and municipal governments. In 2013, the PDIP published a Pharmaceutical Threat Assessment for Pennsylvania that found prescription opioid availability and abuse at epidemic levels...

The Drug Enforcement Administration’s (DEA) Philadelphia Field Division (PFD) Intelligence Program conducted an analysis of drug availability and abuse for the State of Delaware. This product highlights significant findings regarding various drug trends since last reported in 2017. The primary drug threats identified in Delaware are illicit opioids, cocaine, controlled...